Navigation Links
James P. Abely Joins Psychemedics Corporation as Associate General Counsel
Date:6/22/2016

ACTON, Mass., June 22, 2016 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) announced that James P. Abely has joined the company as Associate General Counsel.

In this important role, Jim will be responsible for directing and managing all of the company's legal activities, including working closely with the company's clients.  He will report to the company's CEO.  Jim practiced law with the Boston firm of Goodwin Procter LLP following his graduation from the University of Virginia School of Law. His strong litigation background will be most helpful to Psychemedics and its clients.

Raymond C. Kubacki, Chairman and CEO of Psychemedics, stated, "We are extremely pleased to have Jim joining our team and heading up this important area in our company. Besides providing our clients with the most vigorous drug test available and outstanding client service, we also directly support our clients on any legal challenge.  We not only provide a litigation packet and expert testimony, but also legal assistance for our client's legal team to come up to speed quickly.  That's why this is such an important role in our company and beyond the normal role of Associate General Counsel."

Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, dividends, future business, growth opportunities (including an opportunity in Brazil), new accounts, customer base, market share, test volume, sales and marketing strategies, U.S. and foreign drug testing laws and regulations including effective dates thereof, required investments in plant, equipment and people and new test development) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, costs of capacity expansion, U.S. and foreign government regulation, including but not limited to FDA regulations, Brazilian laws and regulations and projected implementation dates, proposed laws and regulations, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities) and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. Information regarding testing volume for a partial quarter may not necessarily be an indicative of results to be expected for the full quarter or year. The forward-looking statements contained herein speak only of the Company's expecta­tions as of the date of this press release. The Company express­ly disclaims any obligation or undertaking to release publicly any updates or revi­sions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based. 

Contact:
Raymond C. Kubacki
Chairman, President and CEO 
(978) 206-8220

Logo - http://photos.prnewswire.com/prnh/20111107/NE00639LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/james-p-abely-joins-psychemedics-corporation-as-associate-general-counsel-300288685.html


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce
2. Estetique Ramps Up Growth; Appoints James Walker to Board of Directors
3. Mylan to Present at the Raymond James 37th Annual Institutional Investors Conference
4. Haemonetics to Present at the Raymond James 37th Annual Institutional Investors Conference
5. HeartWare Presentation At The Raymond James 37th Annual Institutional Investors Conference To Be Webcast
6. Diplomat to Participate in the Raymond James & Associates 37th Annual Institutional Investors Conference
7. Astellas Names James Robinson President, Americas Operations
8. Aoxing Pharma Appoints Dr. James Chen as Chief Financial Officer
9. Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
10. Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team
11. Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):